세계의 백신 보조제 시장 예측 : 보조제 유형별, 질환 유형별, 백신 유형별, 투여 경로별, 용도별, 최종 사용자별, 지역별 분석(-2030년)

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $0.8 billion in 2024 and is expected to reach $1.4 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Vaccine adjuvants are substances added to vaccines to enhance the immune response to the vaccine antigen. They help create a stronger and longer-lasting immune response, reducing the amount of antigen needed and the number of doses required for immunity. Adjuvants can be immunostimulants that activate the immune system or delivery systems that present the antigen more effectively to immune cells.

According to a report by the World Health Organization (WHO), the global human vaccine market grew from USD 6 billion in 2000 to USD 33 billion in 2014 and USD 36.45 billion in 2018, with sales to high-income countries representing about 65% of the total value.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

As the global burden of infectious diseases continues to grow, there is an increasing demand for effective vaccines to prevent and control these diseases. Adjuvants play a crucial role in enhancing the immunogenicity and efficacy of vaccines, making them more potent and long-lasting. The high incidence rates of infectious diseases such as influenza, malaria, tuberculosis, and emerging pathogens like COVID-19 have further accelerated the need for adjuvanted vaccines. Consequently, the growing prevalence of infectious diseases is propelling the demand for vaccine adjuvants and driving market growth.

Restraint:

High cost of development and manufacturing

The high cost of developing and manufacturing vaccine adjuvants is a significant restraint in the market. The development process is complex, time-consuming, and requires substantial investment in research and development, production facilities, and specialized knowledge. Vaccine development can take a few years, and it comes at a high cost. The high failure rate makes it challenging for manufacturers to secure funds and cover operational expenses.

Opportunity:

Development of new vaccines

As researchers work on vaccines for challenging diseases like HIV, malaria, and cancer, there is a growing need for potent adjuvants to enhance the efficacy of these vaccines. Novel adjuvants can help stimulate stronger and more targeted immune responses, reduce the amount of antigen required, and enable the use of new vaccine delivery methods. Ongoing research into adjuvants such as saponins, TLR agonists, nanoparticles, and mucosal adjuvants holds promise for the development of more effective and innovative vaccines. The increasing demand for new and improved vaccines is expected to drive the growth of the vaccine adjuvant market in the coming years.

Threat:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant threat to the market due to the lengthy and costly approval processes for new adjuvants. Meeting stringent safety and efficacy standards set by regulatory authorities such as the FDA and EMA requires extensive preclinical and clinical data, prolonging product development timelines. Additionally, any regulatory hurdles or delays in approvals can hinder market entry and limit innovation. Adhering to complex regulatory frameworks adds financial burden and uncertainty for companies, impacting their competitiveness and market growth.

Covid-19 Impact:

The COVID-19 pandemic had a positive impact on the vaccine adjuvants market. The urgent need for effective vaccines drove advancements in adjuvant technologies as researchers explored various formulations to enhance immune responses against the virus. This led to increased demand for adjuvants during the pandemic, with the trend expected to persist in the coming years. The crisis accelerated innovations and discoveries in adjuvants that have broader implications for future vaccine development.

The infectious diseases segment is expected to be the largest during the forecast period

The infectious diseases segment is expected to be the largest in the vaccine adjuvants market during the forecast period due to the rising incidence of infectious diseases globally and the urgent need for effective vaccines. Increasing government initiatives and funding for immunization programs, coupled with advancements in adjuvant technology enhancing vaccine efficacy, are driving this growth. Furthermore, heightened awareness of infectious disease prevention and the ongoing development of vaccines targeting emerging pathogens contribute to the dominance of this segment.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR in the vaccine adjuvants market during the forecast period. This is because intramuscular injection is the most common method of vaccine administration, as it allows for efficient delivery of the vaccine to the muscle tissue, which has a rich blood supply and contains immune cells that can quickly respond to the vaccine. Intramuscular administration also reduces the risk of local reactions compared to subcutaneous or intradermal routes. Furthermore, many vaccines containing adjuvants are strongly preferred to be administered intramuscularly to optimize immunogenicity and minimize adverse reactions.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand for vaccine adjuvants in Asia Pacific region.

Region with highest CAGR:

North America is expected to exhibit the highest CAGR in the vaccine adjuvants market during the forecast period due to advanced healthcare infrastructure, robust R&D activities, and significant investments in vaccine development. The region benefits from strong government support, favorable regulatory frameworks, and a high prevalence of infectious diseases, driving the demand for effective vaccines. Additionally, the presence of leading biopharmaceutical companies and increasing awareness about vaccination's importance contribute to the rapid market growth in North America.

Key players in the market

Some of the key players in Vaccine Adjuvants Market include GlaxoSmithKline plc (GSK), CSL Limited, Novavax, Inc., SPI Pharma, Inc., Seppic (Air Liquide), Invivogen, Croda International Plc, Dynavax Technologies Corporation, Adjuvance Technologies Inc., Agenus Inc., OZ Biosciences, Avanti Polar Lipids, Inc., MVP Laboratories, Inc., Vaxine Pty Ltd, GlycoMira Therapeutics Inc., Pfizer Inc., Sanofi Merck & Co., Inc., Zoetis Inc. and Moderna, Inc.

Key Developments:

In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize Novavax's COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines. The deal allows Sanofi to use Novavax's COVID-19 shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products.

In October 2023, SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally.

In July 2023, CSL Seqirus, a business of CSL announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Adjuvants Types Covered:

• Alum (Aluminum Hydroxide)
• Liposomes
• Viral-Derived Particles (VDPs)
• Emulsions
• Carbohydrate Adjuvants
• Tensoactive Adjuvants
• Organic Adjuvants
• Mineral Salt-Based Adjuvants
• Other Adjuvants Types

Disease Types Covered:

• Infectious Diseases
• Cancer
• Other Disease Types

Vaccine Types Covered:

• Viral Vaccines
• Bacterial Vaccines
• Parasitic Vaccines
• Other Vaccine Types

Route of Administration Covered:

• Intramuscular
• Subcutaneous
• Intranasal
• Oral
• Intradermal

Applications Covered:

• Research Application
• Commercial Application

End Users Covered:

• Human Vaccine Adjuvants
• Veterinary Vaccine Adjuvants

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Vaccine Adjuvants Market, By Adjuvant Type

• 5.1 Introduction
• 5.2 Alum (Aluminum Hydroxide)
• 5.3 Liposomes
• 5.4 Viral-Derived Particles (VDPs)
• 5.5 Emulsions
• 5.6 Carbohydrate Adjuvants
• 5.7 Tensoactive Adjuvants
• 5.8 Organic Adjuvants
• 5.9 Mineral Salt-Based Adjuvants
• 5.10 Other Adjuvants Types

6 Global Vaccine Adjuvants Market, By Disease Type

• 6.1 Introduction
• 6.2 Infectious Diseases
• 6.3 Cancer
• 6.4 Other Disease Types

7 Global Vaccine Adjuvants Market, By Vaccine Type

• 7.1 Introduction
• 7.2 Viral Vaccines
• 7.3 Bacterial Vaccines
• 7.4 Parasitic Vaccines
• 7.5 Other Vaccine Types

8 Global Vaccine Adjuvants Market, By Route of Administration

• 8.1 Introduction
• 8.2 Intramuscular
• 8.3 Subcutaneous
• 8.4 Intranasal
• 8.5 Oral
• 8.6 Intradermal

9 Global Vaccine Adjuvants Market, By Application

• 9.1 Introduction
• 9.2 Research Application
• 9.3 Commercial Application

10 Global Vaccine Adjuvants Market, By End User

• 10.1 Introduction
• 10.2 Human Vaccine Adjuvants
• 10.3 Veterinary Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 GlaxoSmithKline plc (GSK)
• 13.2 CSL Limited
• 13.3 Novavax, Inc.
• 13.4 SPI Pharma, Inc.
• 13.5 Seppic (Air Liquide)
• 13.6 Invivogen
• 13.7 Croda International Plc
• 13.8 Dynavax Technologies Corporation
• 13.9 Adjuvance Technologies Inc.
• 13.10 Agenus Inc.
• 13.11 OZ Biosciences
• 13.12 Avanti Polar Lipids, Inc.
• 13.13 MVP Laboratories, Inc.
• 13.14 Vaxine Pty Ltd
• 13.15 GlycoMira Therapeutics Inc.
• 13.16 Pfizer Inc.
• 13.17 Sanofi
• 13.18 Merck & Co., Inc.
• 13.19 Zoetis Inc.
• 13.20 Moderna, Inc.